CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU,
China, Nov. 14,
2024 /PRNewswire/ -- Harbour BioMed (the
"Company"; HKEX: 02142), a global biopharmaceutical company
committed to the discovery, development, and commercialization of
novel antibody therapeutics focusing on oncology and immunology, is
pleased to announce the appointment of Dr. Raymond Zheng as Chief Business Officer (CBO).
Based in the United States, Dr.
Zheng will lead global business development and alliance management
functions, reporting directly to Dr. Jingsong Wang, Founder, Chairman and CEO of
Harbour BioMed.
In his new role, Dr. Zheng will seek to maximize the value of
Harbour BioMed's product portfolio through effective execution of
the Company's partnership initiatives. He will also play a key role
in optimizing resources and coordinating business development
operations globally to support the Company's long-term strategic
goals of investing in and developing transformative medicinal
products to address key unmet medical needs.
Dr. Zheng was initially trained as a scientist and completed a
research fellowship in the field of translational oncology at
Harvard Medical School before joining
the biopharmaceutical industry. Prior to Harbour BioMed, Dr. Zheng
served as founder and CSO of Urica Therapeutics, a clinical-stage
company developing an oral therapy for refractory gout. During his
tenure at Urica, early clinical development was completed, and the
asset was subsequently acquired by a Newco backed by venture
capital committed to supporting its pivotal development. He also
made significant contributions at Fortress Biotech and Agenus as a
business developer where he managed value-added investments and
negotiated transformative partnership transactions.
Dr. Jingsong Wang, Founder,
Chairman and CEO of Harbour BioMed, commented: "Leveraging our
proprietary Harbour Mice® fully human antibody platform,
we have developed a robust and diverse pipeline with potential
first-in-class and best-in-class drug candidates in
immuno-oncology, as well as in inflammatory and immunology
diseases. Raymond's deep expertise in business development and
strategic insights will be invaluable as we expand our
collaborations and accelerate growth in key markets. We are
thrilled to welcome him to the Harbour BioMed family and are
confident that his leadership will significantly enhance the value
of our portfolio."
Dr. Raymond Zheng, Chief Business
Officer of Harbour BioMed, added: "I am honored to join Harbour
BioMed and excited to work alongside a talented team committed to
developing cutting-edge medicinal products. Harbour
Mice® is an industry-leading technology platform that
has gained strong recognition worldwide. I look forward to
leveraging my experience to foster robust partnerships that will
drive the Company's mission and enhance our global impact in the
biopharmaceutical industry."
Dr. Zheng holds a Ph.D. in Cell and Molecular Biology from the
University of California, Riverside,
and an MBA in Finance from Rutgers
University.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical
company committed to the discovery, development, and
commercialization of novel antibody therapeutics focusing on
immunology and oncology. The Company is building its robust
portfolio and differentiated pipeline through internal R&D
capability, collaborations with co-discovery and co-development
partners, and select acquisitions.
The proprietary antibody technology platforms Harbour
Mice® generates fully human monoclonal antibodies
in two heavy and two light chains (H2L2) format, as well as heavy
chain only (HCAb) format. Building upon the HCAb antibodies, the
HCAb-based immune cell engagers (HBICE®) bispecific
antibody technology is capable of delivering tumor-killing effects
unachievable by traditional combination therapies. Integrating
Harbour Mice®, and HBICE® with a single
B cell cloning platform, our antibody discovery engine is highly
unique and efficient for the development of next-generation
therapeutic antibodies. For further information, please refer
to www.harbourbiomed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harbour-biomed-appoints-dr-raymond-zheng-as-chief-business-officer-302306512.html
SOURCE Harbour BioMed